In their analysis of A2ALL registry data, the authors compare out

In their analysis of A2ALL registry data, the authors compare outcomes for patients listed for liver transplantation who had a potential donor evaluated for them. Those who underwent an LDLT were compared with those who underwent a deceased

donor liver transplant (DDLT) or remained on the wait list. These analyses were performed for patients with Model for Endstage Liver Disease (MELD) <15 or ≥15, for patients with and without hepatocellular carcinoma (HCC). With a median follow-up of 4.5 years, the authors report a clear survival benefit of LDLT Selleck Lumacaftor in both low and high MELD patients without HCC when compared to DDLT or remaining on the wait list. For patients with HCC, a survival benefit of LDLT could only be demonstrated for those with MELD of ≥15 when compared to DDLT. For patients with HCC and MELD <15, LDLT and DDLT had similar survival outcomes, which is not surprising given they had similar waiting times at 2.5 months and 3 months, respectively, likely due to the allocation policy for patients with HCC. The finding of a clear survival benefit for non-HCC patients with a MELD <15 who underwent LDLT is somewhat unexpected. A previous

report by PS-341 mw Merion et al.2 demonstrated no survival benefit for deceased donor transplant recipients with a MELD <15 compared to waiting on the list for up to 2 years. This seminal report resulted in a major allocation policy change for patients with MELD <15, and led many in the liver transplant community to conclude that there would be no benefit to transplant for patients with a MELD <15. Importantly, a subsequent report did a show survival benefit down to MELD of 12 when using donors with a low donor risk index (DRI).3 Thus, further analysis of LDLT outcomes across the spectrum of low MELD patients such as between 12-15 and 8-11 may provide additional granularity to the current findings. Because the authors included only patients for whom an available living donor was evaluated, this may reduce potential bias

that may come from a subtle (and immeasurable) survival benefit for patients with enough social support and/or healthy family members that they have a potential living donor compared to Terminal deoxynucleotidyl transferase those wait-listed candidates who have no potential donors. They also controlled for the presence of HCC, hepatitis C virus (HCV), MELD, age, and presence of cholestatic liver disease. Additionally, the authors analyzed the quality of the deceased donor organs in DDLT candidates to ensure that recipients of DDLT in the A2ALL cohort were not getting highly inferior deceased donor organs, which could account for the benefit of LDLT. They compared the DRI of patients receiving deceased donor transplants for both those in the A2ALL study as well as those patients at the participating centers who were not in the study and found it was similar.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>